Aleksandra Stańczak, PhD, Leader of the Oncology Research Team took part in the 7th edition of the conference: “Cancer Molecular Biology in Clinical Practice”, which was held at the end of November 2017 in Warsaw.
At the: conference Ms Stańczak presented the most important assumptions of the project: CELONKO – Development of modern biomarkers and development of an innovative FGFR kinase inhibitor for the treatment of neoplastic diseases.
Aleksandra Stańczak, MD:The CELONKO project implemented in our company has now a permanent place in the debate of the Polish industry and researchers dedicated to the development of new cancer drugs. At present we have finalised the important stage of toxicology studies and are now preparing for the clinical development of our drug candidate.
The conference was organised under the auspices of the Polish Society of Clinical Oncology.
CELONKO is financed under the STRATEGMED II programme.